Therapy of Advanced B-Lymphoma Xenografts With a Combination of 90y-Anti-Cd22 IgG (Epratuzumab) and Unlabeled Anti-Cd20 IgG (Veltuzumab)

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-0404
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)


Related search